nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-B6549FBF·Framework v5.10·Pipeline v0.4·Evaluated 02 Nov 2026·OECD: 3.2 Clinical medicine·Subfield: Genetics·Basis: Full text·Type: Non-randomized or early-phase trial

Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S.

Kinaciyan et al.Kinaciyan, Aygören-Pürsün, Martinez-Saguer et al.·2026·The journal of allergy and clinical immunology. Global·10.1016/j.jacig.2026.100750 ↗

Primary claim

In conclusion, results of this interim analysis of the KONFIDENT-S study demonstrate that sebetralstat is a safe, well-tolerated, and effective on-demand treatment for breakthrough attacks in patients receiving LTP, regardless of the LTP mechanism of action.

Tentative · uncontrolled, self-selected treatment episodes cannot establish causal effectiveness or effectiveness across prophylaxis mechanisms
In brief

A larger descriptive dataset documents sebetralstat use during long-term prophylaxis, but uncontrolled treatment selection prevents its broad effectiveness conclusions.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Abstract

BACKGROUND: Although long-term prophylaxis (LTP) reduces attack frequency in hereditary angioedema, patients may experience breakthrough attacks. Oral sebetralstat demonstrated favorable safety and efficacy compared with placebo in the randomized phase 3 KONFIDENT trial (NCT05259917), including in patients receiving LTP. The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916).

OBJECTIVE: This interim analysis of the KONFIDENT-S study evaluated long-term safety and effectiveness of oral sebetralstat 600 mg for attacks of hereditary angioedema with C1-inhibitor deficiency in participants receiving LTP with lanadelumab, berotralstat, or C1 inhibitor.

METHODS: Efficacy end points included times to beginning of symptom relief, reduction in severity, and complete attack resolution.

RESULTS: As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month). Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours. Effectiveness was similar for participants receiving berotralstat, lanadelumab, or C1 inhibitor. No serious or severe treatment-related treatment-emergent adverse events were reported.

CONCLUSION: Sebetralstat was well tolerated and enabled early on-demand treatment of attacks in patients with hereditary angioedema with C1-inhibitor deficiency receiving LTP. Treatment of breakthrough attacks with sebetralstat resulted in rapid symptom relief, reduction in attack severity, and complete attack resolution, regardless of LTP mechanism of action.

Key Claims

Primary finding · Tentative

In conclusion, results of this interim analysis of the KONFIDENT-S study demonstrate that sebetralstat is a safe, well-tolerated, and effective on-demand treatment for breakthrough attacks in patients receiving LTP, regardless of the LTP mechanism of action.

uncontrolled, self-selected treatment episodes cannot establish causal effectiveness or effectiveness across prophylaxis mechanisms

Discussion, final paragraph
Quote verified
Secondary · Supported

No serious or severe treatment-related treatment-emergent adverse events were reported.

participant-level reporting supports the observed absence, but 35 participants and incompletely described ascertainment limit safety inference

Abstract, Results
Quote verified
Secondary · Tentative

Effectiveness was similar for participants receiving berotralstat, lanadelumab, or C1 inhibitor.

unpowered prophylaxis groups, including six C1INH participants, cannot establish comparative similarity

Abstract, Results
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Larger dataset addresses a documented clinical gap

The analysis reports 382 sebetralstat-treated breakthrough attacks in 35 participants receiving prophylaxis, extending the parent trial's 58 attacks in 24 such participants. This adds descriptive evidence in a concomitant-treatment setting identified as underreported.

↳ Introduction, final three paragraphs; Results, Attack Frequency and Treatment Patterns

#methodological rigour

Safety outcomes retain clear participant denominators

Table III separates serious, severe, treatment-related, and discontinuation events by prophylaxis group. The accompanying text explains both discontinuations and reports no serious or severe sebetralstat-related events.

↳ Table III; Results, Safety

#reporting

Treatment choices and rescue use remain visible

The results distinguish sebetralstat-first, conventional-treatment-first, and untreated attacks, alongside second dosing and rescue treatment. Reporting the greater proportion of laryngeal attacks treated conventionally helps readers assess treatment selection.

↳ Results, Attack Frequency and Treatment Patterns, Treated Attack Characteristics, and Effectiveness

Limitations

#methodological rigour

Uncontrolled attack selection prevents causal effectiveness inference

Participants chose which attacks received sebetralstat first, and effectiveness outcomes were not collected for conventional-treatment-first attacks. Without a concurrent comparator, observed symptom trajectories cannot establish the treatment's causal benefit.

↳ Methods, Study Design and Participants and Primary and Secondary Objectives

#methodological rigour

Primary safety reporting lacks ascertainment and exposure

The paper reports event counts, grading, and relatedness but does not describe how adverse events were elicited or provide subgroup exposure duration. These omissions limit interpretation of its primary safety objective.

↳ Methods, Primary and Secondary Objectives; Table III; Results, Safety

#positioning

Mechanism-wide conclusions contradict acknowledged limits on comparisons

The limitations state that LTP-agent comparisons were unpowered and that the six-participant C1INH group may not be representative. The abstract nevertheless reports similar effectiveness across agents, and the conclusion asserts effectiveness regardless of mechanism.

↳ Abstract, Results and Conclusion; Discussion, Limitations and final paragraph

Does this match your read? Add your assessment ↓

Nabu Commentary

The extension adds clinically relevant treatment-pattern and tolerability observations across 382 attacks, with defined symptom endpoints and participant-level safety reporting. Its central limitation is identification: patients selected initial treatment, and the analysis has neither a concurrent comparator nor a prespecified comparable benchmark. Safety interpretation is also restricted by missing ascertainment and subgroup exposure details. The abstract's agent-similarity statement and the conclusion's mechanism-wide effectiveness claim exceed the paper's own acknowledgment that these comparisons are descriptive and unpowered.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
2.5±0.1

Contribution
3.2

The analysis expands the prior randomized-trial LTP experience from 24 participants and 58 attacks to 35 participants and 382 sebetralstat-treated attacks. It addresses a documented reporting gap, but the advance remains descriptive rather than establishing efficacy or comparability across prophylaxis mechanisms.

Introduction, final three paragraphs; Results, Attack Frequency and Treatment Patterns
Methodological Rigour
1.8

Defined patient-reported endpoints and participant-level safety denominators support descriptive assessment, but primary-safety ascertainment and exposure reporting are incomplete. Uncontrolled, self-selected treatment episodes and promotion of unpowered agent comparisons materially undermine the effectiveness inference.

Methods, Primary and Secondary Objectives and Statistical Analysis; Table III; Abstract, Results; Discussion, Limitations
Reporting
3.2

The sequence of methods, treatment patterns, safety, and symptom outcomes is traceable, with denominators available in the tables. Headline causal and mechanism-wide effectiveness wording is stronger than the descriptive design supports.

Tables II–IV; Abstract, Conclusion; Discussion, final paragraph
Positioning
2.8

The paper engages guidelines, a recent systematic review, and the parent randomized trial to establish its clinical niche. Its final conclusion does not preserve the explicitly stated limits on causal inference and LTP-agent comparisons.

Introduction; Discussion, Limitations and final paragraph

Lower confidence on Methodological Rigour — domain match limited.

Reliability

Caveats4 of 4 checks


Results checkNoted

2 reported values do not reconcile, but the key claims do not rest on them.

  • Treatment of breakthrough attacks with sebetralstat resulted in rapid symptom relief: "Of the 382 attacks, 264 (69.1%) obtained beginning of symptom relief within 12 hours." (Results, Effectiveness) vs "Median (IQR) time to beginning of symptom relief was 1.3 (0.8-3.8) hours for participants receiving any LTP" (Results, Effectiveness). Under an uncensored empirical-distribution approximation, 69.1% reaching relief by 12 hours would place the upper quartile beyond 12 hours, but censoring may explain the reported 3.8-hour quartile. → Effect on result unclear
Reporting and transparencyNoted

Ethics approval, consent, trial registrations, funding, and conflicts are declared. The reported 6-minute treatment interval is inconsistently labeled as beginning at attack recognition or attack onset.

Conflict of interest: declared · Ethics approval: declared · Preregistration: declared

Reference IntegrityClean

46 references in manuscript 26 of 26 checkable references found in an index 20 are books, websites or datasets — counted, but not index-checkable

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 02 Nov 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Metabolic and endocrine · Endocrine, metabolic, blood, and immune disorders
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesCatch-all cause
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessValidated
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

A multicenter open-label extension across North American, European, and Asia-Pacific sites treated 382 breakthrough attacks, corroborating the randomized phase 3 trial in a larger confirmatory setting.

From the paper
“These data support the role of sebetralstat as an important component of HAE management.”

The conclusion names a concrete real-world use of sebetralstat within HAE management practice but identifies no specific profession, organisation, or decision-setting that would apply it.

Pathway

Allergists and immunologists managing HAE, and patients themselves, could adopt oral sebetralstat for early on-demand treatment of breakthrough attacks during long-term prophylaxis.

Barrier

The open-label, descriptive, uncontrolled design limits causal inference, and the small C1INH-prophylaxis subgroup plus lack of powering for between-agent comparisons leave generalizability uncertain.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Oral Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks

    Riedl, Farkas, Aygören-Pürsün, et al. · 2024 · Clinical medicine

    Primary claim

    Oral sebetralstat provided faster times to the beginning of symptom relief, reduction in attack severity, and complete attack resolution than placebo.

    Well-supported
    Evidence Score
    4.2±0.2
    Reliability
    No concerns
  2. Efficacy and Safety of Donidalorsen for Hereditary Angioedema

    Riedl, Tachdjian, Lumry, et al. · 2024 · Clinical medicine

    Primary claim

    Donidalorsen at a dose of 80 mg administered subcutaneously every 4 or 8 weeks significantly reduced the hereditary angioedema attack rate

    Supported
    Evidence Score
    4.0±0.1
    Reliability
    Caveats
  3. CRISPR-Based Therapy for Hereditary Angioedema

    Cohn, Gurugama, Magerl, et al. · 2024 · Clinical medicine

    Primary claim

    NTLA-2002 administered in a single dose of 25 mg or 50 mg reduced angioedema attacks and led to robust and sustained reduction in total plasma kallikrein levels in patients with hereditary angioedema.

    Tentative
    Evidence Score
    3.6±0.1
    Reliability
    Caveats

How the rubric works →